Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 3/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415954 | 1.00 | RHOA (0.47) | RHOAMEN1KMT2AL3MBTL1CSNK2A1 | |
| SCHEMBL6413574 | 0.90 | GSK3B (0.40) | RHOAMEN1KMT2ACSNK2A1ABCG2 | |
| SCHEMBL6413560 | 0.90 | GSK3B (0.40) | RHOAMEN1KMT2ACSNK2A1ABCG2 | |
| SCHEMBL6435294 | 0.88 | CBS (0.45) | RHOAMEN1KMT2AL3MBTL1CSNK2A1 | |
| SCHEMBL6435311 | 0.88 | CBS (0.45) | RHOAMEN1KMT2AL3MBTL1CSNK2A1 | |
| SCHEMBL6414707 | 0.88 | PIM1 (0.40) | RHOAMEN1KMT2AL3MBTL1ABCG2 | |
| SCHEMBL6414695 | 0.88 | PIM1 (0.40) | RHOAMEN1KMT2AL3MBTL1ABCG2 | |
| SCHEMBL6413428 | 0.85 | BIRC5 (0.47) | RHOAMEN1KMT2AL3MBTL1CSNK2A1 | |
| SCHEMBL6415701 | 0.85 | CSNK2A1 (0.45) | CSNK2A1ABCG2CSNK2A2CSNK2BNPC1 | |
| SCHEMBL6415683 | 0.85 | CSNK2A1 (0.45) | CSNK2A1ABCG2CSNK2A2CSNK2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | RHOA 4723/4885MEN1 4392/4885KMT2A 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.